Is Karyopharm Therapeutics Inc. overvalued?

Karyopharm Therapeutics Inc. (KPTI) — key valuation metrics and fundamentals.

No verdict

Price

$2.02

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$45.8M

Dividend yield

0.0%

Return on equity

73.1%

Sector

Healthcare

Fair value compares KPTI's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Aug 2026.

Related stocks